AU2013334139B2 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome - Google Patents

Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome Download PDF

Info

Publication number
AU2013334139B2
AU2013334139B2 AU2013334139A AU2013334139A AU2013334139B2 AU 2013334139 B2 AU2013334139 B2 AU 2013334139B2 AU 2013334139 A AU2013334139 A AU 2013334139A AU 2013334139 A AU2013334139 A AU 2013334139A AU 2013334139 B2 AU2013334139 B2 AU 2013334139B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013334139A
Other languages
English (en)
Other versions
AU2013334139A1 (en
Inventor
Roland Werner BURLI
William Rameshchandra Krishna ESMIEU
William Edward HARTE
Christopher James Lock
Karine Fabienne MALAGU
Andrew Pate Owens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Usher III Initiative Inc
Original Assignee
Usher III Initiative Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usher III Initiative Inc filed Critical Usher III Initiative Inc
Publication of AU2013334139A1 publication Critical patent/AU2013334139A1/en
Application granted granted Critical
Publication of AU2013334139B2 publication Critical patent/AU2013334139B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2013334139A 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome Active AU2013334139B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718611P 2012-10-25 2012-10-25
US61/718,611 2012-10-25
US201361775402P 2013-03-08 2013-03-08
US61/775,402 2013-03-08
PCT/US2013/066939 WO2014066836A1 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Publications (2)

Publication Number Publication Date
AU2013334139A1 AU2013334139A1 (en) 2015-04-30
AU2013334139B2 true AU2013334139B2 (en) 2017-08-03

Family

ID=50545356

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013334139A Active AU2013334139B2 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome

Country Status (10)

Country Link
EP (1) EP2911671B1 (enExample)
JP (1) JP6291502B2 (enExample)
AU (1) AU2013334139B2 (enExample)
CA (1) CA2889494C (enExample)
ES (1) ES2687854T3 (enExample)
HU (1) HUE039970T2 (enExample)
IL (1) IL238288B (enExample)
PL (1) PL2911671T3 (enExample)
WO (1) WO2014066836A1 (enExample)
ZA (1) ZA201502655B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2834049C (en) 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP6290910B2 (ja) * 2012-10-25 2018-03-07 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
WO2017045955A1 (en) * 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
WO2020161209A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
WO2020161208A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
WO2022011091A1 (en) 2020-07-09 2022-01-13 Usher Iii Initiative, Inc. Treatment of cancer, inflammatory diseases and autoimmune diseases
WO2023139091A1 (en) * 2022-01-19 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Geralexin and uses thereof for the treatment of retinal degenerative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148994A1 (en) * 2011-04-25 2012-11-01 Usher Iii Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206723D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel compounds
US20090306045A1 (en) * 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
CN101917999A (zh) * 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
JP6290910B2 (ja) * 2012-10-25 2018-03-07 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148994A1 (en) * 2011-04-25 2012-11-01 Usher Iii Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Tretyakov, E. V. et al. "Investigations of the Richter reaction in a series of vicinal alkynylpyrazolediazonium salts", Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry, 1999, (24), 3721-3726 *
Tretyakov, E. V. et al. "New findings in the Richter reaction in series of vicinal alkynylpyrazolyldiazonium salts ", Heterocyclic Communications, 1998, 4(6), 519-524 *
Vasilevsky, S. F. et al. "Cinnolines and pyrazolopyridazines. -Novel synthetic and mechanistic aspects of the Richter reaction", Liebigs Annalen, 1995, 775-7799 *

Also Published As

Publication number Publication date
EP2911671B1 (en) 2018-06-27
HUE039970T2 (hu) 2019-02-28
IL238288A0 (en) 2015-06-30
HK1214180A1 (en) 2016-07-22
PL2911671T3 (pl) 2018-11-30
ZA201502655B (en) 2017-11-29
WO2014066836A1 (en) 2014-05-01
EP2911671A4 (en) 2016-09-14
ES2687854T3 (es) 2018-10-29
JP6291502B2 (ja) 2018-03-14
CA2889494C (en) 2018-12-18
AU2013334139A1 (en) 2015-04-30
EP2911671A1 (en) 2015-09-02
JP2015535257A (ja) 2015-12-10
IL238288B (en) 2018-04-30
CA2889494A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
EP2911671B1 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9783545B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
CN103732583B (zh) Trpv4拮抗剂
KR102522832B1 (ko) 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 피라졸로［１，５―ａ］피리미딘 유도체
AU2012249801B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome
EP2640723A1 (en) Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2011221075B2 (en) Pyrazolopyrimidine compounds and their use as PDE10 inhibitors
WO2008134035A1 (en) Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives
EP1377585B1 (en) Novel 10-cyclohexenyl-phenyl pyrrolobenzodiazepine-3-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
JP2023539985A (ja) 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体
TW201625616A (zh) 作為ｒｓｖ抗病毒化合物之螺脲化合物
US11981658B2 (en) Substituted aminopyridine compounds as EGFR inhibitors
AU2013334138B2 (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome
HK1214180B (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP7776616B2 (ja) Ｐｄ－ｌ１相互作用の免疫調節剤としての化合物
WO2025160079A1 (en) Indazolo-amino-pyrimidinone compounds
EP4714953A1 (en) Melanocortin 2-type receptor antagonist
HK1195507A (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)